New research may give geneticists a long-sought tool; biopharma under pressure to take climate action

New research from a CRISPR pioneer offers a potential solution to delivery challenges that have long stunted genetic medicine.

March 29, 2023 Check out STAT+

Sponsored By

Des Helmore/Manaaki Whenua – Landcare Research STAT+ | New research may give geneticists a long-sought tool: a targeted protein delivery device The research, from the lab of CRISPR pioneer Feng Zhang, offers a potential solution to challenges that have long stunted genetic medicine. By Jason Mast Under pressure, biotech and pharma grapple with how to take climate action The health impact of climate change: Biotech and pharma companies are under pressure to take climate action and reduce carbon emissions. By Betsy Ladyzhets STAT+ | British Columbia to bar Americans from buying Ozempic over supply concerns As more Americans seek out diabetes drug Ozempic to help them lose weight, British Columbia plans to limit sales to Canadian residents. By Elaine Chen Wong Maye-E/AP STAT+ | Shortage of monkeys for early-stage research jeopardizes timelines for developing some drugs A shortage of monkeys used for research is causing concern that many drug companies will soon face costly delays starting clinical trials, By Ed Silverman and Damian Garde STAT+ | Medical device companies now need to prove to FDA they're protected against cyberattacks Companies can no longer sell medical devices connected to the internet without first showing the FDA a solid cybersecurity plan. By Lizzy Lawrence FDA approves over-the-counter Narcan. Here's what it means Advocates have long sought approval for Narcan to improve access to a lifesaving drug, though the exact impact will not be clear immediately. By Geoff Mulvihill — Associated Press Sunday Alamba/AP Cases of Marburg going unreported in Equatorial Guinea, WHO says The executive director of the agency's health emergencies program expressed some exasperation about reporting delays by the country. By Helen Branswell New lupus partnership with FDA aims to end drug trials' history of failure With just three lupus drugs approved in six decades, the FDA will work with researchers and patients to look for better strategies. By Isabella Cueto

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Daily Recap? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2023, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser